Zuckerman Jane N, Rombo Lars, Fisch Alain
Academic Centre for Travel Medicine and Vaccines, WHO Collaborating Centre for Travel Medicine, Royal Free and University College Medical School, London, UK.
Lancet Infect Dis. 2007 Aug;7(8):521-30. doi: 10.1016/S1473-3099(07)70138-X.
Cholera is a substantial health burden on the developing world and is endemic in Africa, Asia, South America, and Central America. The exact scale of the problem is uncertain because of limitations in existing surveillance systems, differences in reporting procedures, and failure to report cholera to WHO; official figures are likely to greatly underestimate the true prevalence of the disease. We have identified, through extensive literature searches, additional outbreaks of cholera to those reported to WHO, many of which originated from the Indian subcontinent and southeast Asia. Such underestimation of cholera can have important implications for decisions on provision of health interventions for indigenous populations, and on risk assessments for travellers. Furthermore, until recently, it has not been possible to implement public-health interventions in low-income countries to eliminate disease, and the prevention of cholera in travellers has been limited to restrictive guidelines. However, a vaccine against cholera is now available that has proven efficacy and tolerability in mass vaccination campaigns in low-income countries, and among travellers.
霍乱给发展中世界带来了沉重的健康负担,在非洲、亚洲、南美洲和中美洲呈地方流行。由于现有监测系统存在局限性、报告程序不同以及未向世界卫生组织报告霍乱情况,问题的确切规模尚不确定;官方数据很可能大大低估了该疾病的实际流行程度。通过广泛的文献检索,我们发现了一些未向世界卫生组织报告的霍乱疫情,其中许多起源于印度次大陆和东南亚。对霍乱的这种低估可能会对为当地居民提供卫生干预措施的决策以及旅行者的风险评估产生重要影响。此外,直到最近,在低收入国家实施公共卫生干预措施以消除疾病仍无法实现,而旅行者霍乱的预防措施一直局限于限制性指南。然而,现在有一种霍乱疫苗可供使用,该疫苗在低收入国家的大规模疫苗接种运动以及旅行者中已证明具有疗效和耐受性。